Calidi Biotherapeutics (CLDI) Income from Continuing Operations (2022 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Income from Continuing Operations of 4045000.0 for Q4 2025, up 2.48% year-over-year from 3946991.3 in Q4 2024, and up 21.93% quarter-over-quarter from 5181000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Calidi Biotherapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 4045000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 2.48% year-over-year to 4045000.0; the TTM figure through Dec 2025 stood at 20049000.0 (up 9.73% YoY), while the FY2025 annual figure was 20049000.0, up 9.73% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 4045000.0, up from 5181000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4161210.0 in Q2 2022, with the low at 12501000.0 in Q2 2023.
- The 4-year median for Income from Continuing Operations is 5268000.0 (2022), against an average of 4935099.81.
- Peak annual rise in Income from Continuing Operations reached 62.2% in 2023, while the deepest fall reached 541.94% in 2023.
- Calidi Biotherapeutics' Income from Continuing Operations stood at 7756000.0 in 2022, then fell by 6.1% to 8229000.0 in 2023, then jumped by 49.59% to 4148000.0 in 2024, then rose by 2.48% to 4045000.0 in 2025.
- Business Quant data shows CLDI's Income from Continuing Operations at 4045000.0 in Q4 2025, 5181000.0 in Q3 2025, and 5761000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | -4.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.16 Mn |
| Dec 31, 2025 | -4.05 Mn |
| Sep 30, 2025 | -5.18 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Dec 31, 2024 | -4.15 Mn |
| Sep 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -7.23 Mn |
| Dec 31, 2023 | -8.23 Mn |
| Sep 30, 2023 | -2.02 Mn |
| Jun 30, 2023 | -12.50 Mn |
| Mar 31, 2023 | -6.46 Mn |
| Dec 31, 2022 | -7.76 Mn |
| Sep 30, 2022 | -5.36 Mn |
| Jun 30, 2022 | 4.16 Mn |
| Mar 31, 2022 | 1.46 Mn |